Overview

• CDSCO approved Ozempic (semaglutide) on September 26 for adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise.
• Novo Nordisk is reported to be preparing a once-weekly rollout in India, but the company has not disclosed pricing or an exact launch date.
• In India the medicine will be available only with a doctor’s prescription, according to sources cited in the approval coverage.
• Semaglutide is a GLP-1 analogue that improves blood sugar control and supports weight loss, with studies reporting cardiovascular and kidney benefits in certain patients.
• Common side effects are gastrointestinal; clinical data cited in reports note nausea occurs in about 20% of users at 0.5 mg or 1 mg doses, and experts expect generic competition after a reported March 2026 patent expiry.